Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036

Rhea-AI Filing Summary

Aurinia Pharmaceuticals director Kathleen Goetz received a grant of 23,931 Director Stock Options on June 4, 2026. These options give her the right to buy an equal number of common shares at an exercise price of 15.67 per share and expire on June 4, 2036.

The options were granted as compensation, not purchased in the market, and vest one year from the date of grant. Following this award, her reported derivative holdings from this grant total 23,931 options, all held directly.

Insights

Equity compensation analyst

Routine director option grant with long-dated strike price.

Kathleen Goetz, a director of Aurinia Pharmaceuticals, received 23,931 stock options as a compensation grant, not a market trade. The options carry an exercise price of 15.67 per share and expire on June 4, 2036.

The filing notes that the options vest one year from the grant date, so economic value depends on continued service and future share performance. There are no accompanying sales or exercises, and the transaction is classified as a routine grant/award acquisition.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Goetz Kathleen

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	23,931	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 23,931 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 23,931 options Exercise price: 15.67 per share Expiration date: June 4, 2036 +1 more

4 metrics

Options granted 23,931 options Director stock option grant on June 4, 2026

Exercise price 15.67 per share Conversion or exercise price of options

Expiration date June 4, 2036 Option expiration for the director grant

Derivative holdings after grant 23,931 options Total options following the reported transaction

Key Terms

Director Stock Option (right to buy), exercise price, Grant, award, or other acquisition, Common Shares, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: "Director Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "15.6700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

vest financial

"The options shall vest one year from date of grant."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goetz Kathleen

(Last) (First) (Middle)

#140, 14315-118 AVENUE

(Street)

EDMONTON T5L 4S6

(City) (State) (Zip)

ALBERTA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$15.67	06/04/2026		A		23,931		(1)	06/04/2036	Common Shares	23,931	$0	23,931	D

Explanation of Responses:

1. The options shall vest one year from date of grant.

Remarks:

	/s/ Kathleen Goetz	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Aurinia Pharmaceuticals (AUPH) director Kathleen Goetz report in this Form 4?

Kathleen Goetz reported receiving a grant of stock options as a director of Aurinia Pharmaceuticals. The award covers 23,931 Director Stock Options linked to common shares, reflecting equity-based compensation rather than an open-market purchase or sale of existing shares.

How many stock options did Kathleen Goetz receive from Aurinia Pharmaceuticals (AUPH)?

She received 23,931 Director Stock Options tied to Aurinia Pharmaceuticals common shares. Each option represents the right to purchase one common share, so the grant covers 23,931 underlying shares if the options eventually vest and are exercised in the future.

What is the exercise price and expiration date of Kathleen Goetz’s Aurinia (AUPH) options?

The options have an exercise price of 15.67 per share and expire on June 4, 2036. This means she can buy Aurinia common shares at 15.67 per share any time after vesting and before the June 4, 2036 expiration date, subject to plan terms.

When do Kathleen Goetz’s Aurinia Pharmaceuticals (AUPH) options vest?

According to the footnote, the options vest one year from the date of grant. Since the grant date is June 4, 2026, vesting is scheduled to occur one year later, assuming continued service and satisfaction of any applicable plan conditions during that period.

Did Kathleen Goetz buy or sell Aurinia (AUPH) shares on the open market in this filing?

No open-market buys or sells were reported in this filing. The transaction is classified as a grant or award acquisition of derivative securities, meaning she received new stock options as compensation rather than trading existing Aurinia common shares in the market.

What are Kathleen Goetz’s reported derivative holdings in Aurinia (AUPH) after this grant?

Following the transaction, the Form 4 shows she directly holds 23,931 Director Stock Options from this award. These options correspond to 23,931 underlying common shares and represent her reported derivative position related to this specific grant at the time of the filing.